Swiss generic medicines firm Sandoz said on Tuesday that it had reached a $275 million settlement with plaintiffs in a legacy US generic drug antitrust lawsuit.
Sandoz and subsidiary Fougera Pharmaceuticals reached a settlement in a drug price cartel case that saw a class action lawsuit in a court in Pennsylvania.
The Swiss group stated that the amicable agreement — which remains subject to court approval — did not contain an admission of fault.
Sandoz recorded in its 2024 accounts a provision of $265 million for other complaints still pending, specifying that its financial objectives for the year are not affected.
